Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
The current study will not only assess the effectiveness of osimertinib treatment in a real world setting, but will also help us to understand the real-world testing patterns among T790M mutation positive locally advanced or metastatic NSCLC patients who have progressed after EGFR TKI treatment.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Above 18 years of age;
Locally advanced (stage IIIB) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy
Confirmed T790M mutation
Progressed on previous EGFR TKI treatment. Patients may have also received additional lines of treatment
Received osimertinib treatment in the participating site between May 1st and Oct 31st 2016
You may not be if
Enrolment in studies that prohibit any participation in this observational study